Robert Eckert net worth and biography

Robert Eckert Biography and Net Worth

Director of Amgen
Robert A. Eckert is our lead independent director. Mr. Eckert has been an Operating Partner at FFL Partners, LLC (formerly known as Friedman Fleischer & Lowe, LLP), a private equity firm, since 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacture and marketing company, having held this position from 2000 through 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992.

Mr. Eckert has been a director of McDonald’s Corporation, a company that franchises and operates McDonald’s restaurants in the global restaurant industry, since 2003, serving as the Chair of the Public Policy and Strategy Committee and a member of the Executive and Governance Committees. Mr. Eckert also has served as a director of Levi Strauss & Co., a jeans and casual wear manufacturer, since 2010, serving as Chair of the Nominating, Governance and Corporate Citizenship Committee and a member of the Compensation Committee and, since March 2021, as non-executive Chair of the board. In 2020, Mr. Eckert was appointed a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, serving as Chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Eckert was a director of Smart & Final Stores, Inc., a warehouse store, from 2013 until 2014 prior to it becoming a publicly-traded company. He was appointed director of Eyemart Express Holdings LLC, a privately-held eyewear retailer and portfolio company of FFL Partners, LLC, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona. Mr. Eckert received an undergraduate degree from the University of Arizona and a master’s degree in business administration from the Kellogg School of Management at Northwestern University.

What is Robert Eckert's net worth?

The estimated net worth of Robert Eckert is at least $4.81 million as of August 18th, 2022. Mr. Eckert owns 21,184 shares of Amgen stock worth more than $4,808,132 as of September 26th. This net worth approximation does not reflect any other assets that Mr. Eckert may own. Learn More about Robert Eckert's net worth.

How do I contact Robert Eckert?

The corporate mailing address for Mr. Eckert and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected] Learn More on Robert Eckert's contact information.

Has Robert Eckert been buying or selling shares of Amgen?

During the past quarter, Robert Eckert has sold $1,643,400.00 in shares of Amgen stock. Most recently, Robert Eckert sold 6,600 shares of the business's stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $249.00, for a transaction totalling $1,643,400.00. Following the completion of the sale, the director now directly owns 21,184 shares of the company's stock, valued at $5,274,816. Learn More on Robert Eckert's trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Robert Bradway (Chairman & CEO), Robert Eckert (Director), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, insiders at the medical research company sold shares 4 times. They sold a total of 20,900 shares worth more than $5,107,827.00. The most recent insider tranaction occured on August, 22nd when Director R Sanders Williams sold 200 shares worth more than $49,992.00. Insiders at Amgen own 0.5 % of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 8/22/2022.

Robert Eckert Insider Trading History at Amgen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2022Sell6,600$249.00$1,643,400.0021,184View SEC Filing Icon  
See Full Table

Robert Eckert Buying and Selling Activity at Amgen

This chart shows Robert Eckert's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $226.97
Low: $224.56
High: $228.61

50 Day Range

MA: $242.97
Low: $224.46
High: $253.15

2 Week Range

Now: $226.97
Low: $198.64
High: $258.45

Volume

2,148,700 shs

Average Volume

3,053,114 shs

Market Capitalization

$121.41 billion

P/E Ratio

19.23

Dividend Yield

3.42%

Beta

0.56
Goldman Sachs Alum Sounds Alarm on "Next US Crisis"
Few believed Nomi Prins when she called the 2008 meltdown well in advance. Now, she's issuing a new prediction. Most Americans aren't yet prepared.
Learn more.